ADH-1: Difference between revisions
Tom.Reding (talk | contribs) m →top: vauthors/veditors or enumerate multiple authors/editors (CS1 maintenance), WP:GenFixes using AWB |
No edit summary Tag: extraneous markup |
||
| Line 21: | Line 21: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
UJHOIJH'''Bold text''' |
|||
<!-- Pharmacokinetic data --> |
<!-- Pharmacokinetic data --> |
||
| bioavailability = |
| bioavailability = |
||
| Line 27: | Line 27: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion AND AISYAH = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
Revision as of 06:35, 1 October 2016
 | |
| Clinical data | |
|---|---|
| Trade names | Exherin |
| Routes of administration | UJHOIJHBold text |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H34N8O6S2 |
| Molar mass | 570.69 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADH-1 (brand name Exherin) is a small, cyclic pentapeptide vascular-targeting drug.
ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis.[1] N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell–cell adhesion and signaling mechanisms;[1] may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.[1]
In a pilot study (phase I trial) at Duke Comprehensive Cancer Center, ADH-1 intravenous pretreatment before chemotherapy in metastatic melanoma completely destroyed tumors in half the patients, normally a very deadly cancer. It is being investigated for advanced extremity melanoma in phase II trials.[2][3]
References
- ^ a b c "ADH-1". NCI Drug Dictionary.
- ^ Yarom N, Stewart D, Malik R, Wells J, Avruch L, Jonker DJ (Feb 1, 2013). "Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors". Curr Clin Pharmacol. 8 (1): 81–88. PMID 22280327.
- ^ Physorg:Drug combination may be effective against deadly melanoma, pilot study shows
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |